Form 4 for ABBV AbbVie
Accepted 2022-02-22 00:00:00 ET · period of report 2022-02-17 · accession 0001179110-22-001513 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2022-02-22 | 2022-02-17 | ABBV | Gosebruch Henry O | EVP, Chief Strategy Off | A - Grant | $0.00 | +68.1K | 86.8K | +364% | $0 |
| D | 2022-02-22 | 2022-02-17 | ABBV | Gosebruch Henry O | EVP, Chief Strategy Off | A - Grant | $0.00 | +30.6K | 30.6K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock, $0.01 par value | 2022-02-17 | A | A | 7,972 | $0.00 | 63,356 | D | — | — | (F2) Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 21, 2019. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022. |
| 2 | Common | Common Stock, $0.01 par value | 2022-02-17 | A | A | 14,722 | $0.00 | 78,078 | D | — | — | (F3) Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 20, 2020. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022. |
| 3 | Common | Common Stock, $0.01 par value | 2022-02-17 | A | A | 36,673 | $0.00 | 55,384 | D | — | — | (F1) Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 21, 2019. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors Board of Directors. The shares will be issued to the reporting person on February 28, 2022. |
| 4 | Common | Common Stock, $0.01 par value | 2022-02-17 | A | A | 8,701 | $0.00 | 86,779 | D | — | — | (F4) Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022. |
| 5 | Derivative | Option (right to buy) | 2022-02-17 | A | A | 30,647 | $0.00 | 30,647 | D | $144.54 · 2023-02-17 to 2032-02-16 | 30,647 Common Stock | (F7) Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 10,216 on February 17, 2023, 10,216 on February 17, 2024, and 10,215 on February 17, 2025. |